Sekisui Diagnostics has introduced a new rapid testing solution for respiratory syncytial virus (RSV), designed to be used in professional healthcare environments.
The OSOM RSV Test detects RSV nucleoprotein antigen using anterior nasal swab specimens, and is claimed to deliver results within 15 minutes. It is Clinical Laboratory Improvement Amendments (CLIA)-waived, allowing it to be used at the point-of-care.
The test is said to differ from conventional rapid RSV antigen tests by targeting a wider range of patients. It is approved for use in children aged six months to six years and adults aged 60 and above, addressing two groups at higher risk for severe RSV infection.
Sekisui Diagnostics vice president and point-of-care business unit general manager Harold Chan said: “With the overlapping symptoms of common respiratory infections and the disparate treatment protocols for each, it is more critical than ever to provide accurate and timely results.
“Now that there are different treatment options on the market, we found it extremely important to expand our respiratory portfolio to provide healthcare professionals diagnostic solutions to improve the health of their patients.”
Sekisui Diagnostics is engaged in providing a variety of rapid diagnostic solutions under its OSOM, Metrix, and Acucy brands, serving both professional and home testing markets.
In April 2025, Sekisui Diagnostics launched the Metrix COVID/Flu Test as part of the Metrix Molecular Platform. This test is available for both point-of-care and home settings.
An exclusive distribution agreement with Aptitude Medical Systems was established in January 2024 to distribute the Aptitude Metrix COVID-19 Test in the US.
Following US Food and Drug Administration (FDA) authorisation, Sekisui Diagnostics now offers the COVID/Flu combination test. This molecular test differentiates RNA from SARS-CoV-2, Influenza A, and Influenza B using anterior nares swab samples, with results ready in 20 minutes and minimal hands-on time required.
